It has also been demonstrated that the novel system using MMP9-responsive MSNs could be used to effectively control site-selective drug delivery in a combination of two drugs (bortezomib and cisplatin) to achieve the optimal synergistic effect on the therapeutic efficiency of lung cancer (Figure 4F) (79). Here, MMP9 is linked to lung cancer.